The medicine is primarily relevant for use in conditions associated with active bacterial infections in horses. It is commonly used to help with infections, aiming to address the bacterial source and provide support that helps ease the overall symptom burden. The range of use for this medicine is indicated for conditions involving systemic or localized bacterial presence.

Treatment of Acute Systemic and Localized Infections

This medicine is relevant in clinical settings that involve acute or unstable symptom patterns, such as those related to systemic imbalance and organ-specific functional stress. It is applied across conditions presenting with acute episodes of bacterial infection, including respiratory conditions like pneumonia, urogenital infections, and the management of wound infections.

Its use helps address symptom clusters that may become intense or disruptive, especially when associated with high fever and profound lethargy. The medicine offers support that helps ease the overall symptom burden and may assist with maintaining a sense of stability when symptoms interfere with daily functioning, such as mobility.

“The medicine offers support that helps ease the overall symptom burden and may assist with maintaining a sense of stability during symptomatic phases.”

---

Quick Fact: Supportive Role in Systemic Discomfort

This medicine is relevant for managing symptoms related to systemic imbalance, such as fever and lethargy, in contexts involving heightened systemic burden.

Regulatory References

1. U.S. FDA Drug Label for UNIPRIM® Powder for Horses

Official Eligibility Profile for Equibactin (Horse Medicine)

This section outlines who is and is not eligible to receive Equibactin (trimethoprim/sulfadiazine) based exclusively on authoritative governmental regulatory documents (e.g., EMA, VMD, FDA labeling) for veterinary use in horses.

Contraindications (Must Not Use)

Equibactin is contraindicated and must not be administered to horses that meet any of the following criteria, as these are absolute exclusions stated in the regulatory label:

• Horses with a known hypersensitivity (allergy) to the active substances (sulfonamides or trimethoprim) or any excipients.
• Horses with known serious hepatic insufficiency (severe liver disease).
• Horses with known serious renal insufficiency (severe kidney disease).
• Horses with documented blood dyscrasias (disorders of the blood).
• Horses with known resistance to the trimethoprim/sulfonamide combination.

Restricted and Conditional Use

Certain populations may be eligible only under specific, documented conditions:

• Food Chain Exclusion: Use is not permitted in mares producing milk intended for human consumption.
• Pregnancy and Lactation: The safety of Equibactin has not been established in pregnant or lactating mares. Its use in these animals must be avoided unless a formal benefit/risk assessment by the responsible veterinarian justifies treatment.
• Age and Organ Status: Caution should be exercised when treating new-born animals and horses with liver damage or other renal impairments, as these states increase the risk of side effects or drug accumulation. The minimum treatment body weight is generally defined.

Interactions with other medicines and products

Equibactin (Sulfadiazine/Trimethoprim) is a potentiated sulfonamide combination whose interaction profile is strictly defined by regulatory documentation concerning specific co-administered substances and administration conditions.

Documented Drug-Drug and Drug-Food Interactions

The most significant restriction documented in official labeling involves a serious pharmacodynamic interaction with Detomidine, an alpha2-adrenoceptor agonist. Co-administration with Detomidine is classified as a contraindicated combination because it is known to be capable of causing fatal arrhythmias in the horse.

Beyond this prohibited drug combination, the official profile includes a clinically relevant pharmacokinetic interaction concerning oral administration with food.

Interacting Entity	Interaction Classification	Official Outcome/Restriction
Detomidine	Pharmacodynamic Interaction	Formally Contraindicated due to risk of fatal cardiac arrhythmias.
Food	Pharmacokinetic Interaction	Decreased systemic absorption of the trimethoprim component.

Regulatory sources indicate that the presence of food during oral administration specifically reduces the exposure of trimethoprim but does not affect the absorption of sulfadiazine. These constraints—a severe combination prohibition and a conditional alteration of exposure—constitute the key regulatory requirements for co-administration considerations.

The mechanism of Equibactin (Sulfadiazine/Trimethoprim) is defined by its selective disruption of the microbial life cycle through an anti-metabolite strategy. The combined action targets two consecutive, essential steps in the bacterial machinery, resulting in a bactericidal effect while demonstrating a high degree of selective toxicity toward microbial enzymes.

Sequential Blockade of Bacterial Folic Acid Synthesis

This mechanism involves a sequential double blockade of the bacterial metabolic pathway responsible for producing essential folate coenzymes. Sulfadiazine acts as a competitive inhibitor of Dihydropteroate Synthase (DHPS), while Trimethoprim inhibits Dihydrofolate Reductase (DHFR). This dual, synergistic inhibition results in the arrest of microbial synthesis of critical components for growth.

Irreversible Depletion of Genetic Building Blocks

By preventing the formation of Tetrahydrofolate (THF), the drug critically depletes the bacterial cell of precursors necessary for DNA, RNA, and protein synthesis. This profound lack of genetic building blocks corresponds to the complete and irreversible arrest of replication and metabolic function in susceptible bacterial organisms.

Potentiated Selectivity and Mechanism Limitations

The synergistic action is rooted in Trimethoprim’s vastly greater affinity for the bacterial DHFR enzyme compared to the host’s analogous enzyme. The mechanism is constrained, however, by bacterial ability to develop resistance, primarily through mutations in the target enzymes or by acquiring the ability to bypass the synthesis pathway by using exogenous folate.

How Equibactin is Used: Administration Guidelines

Equibactin is a veterinary potentiated sulfonamide antibiotic intended strictly for oral administration in horses. The general principle for its use is based on precise, weight-dependent calculation and established administration techniques.

Dosage and Frequency

The typical dosing regimen is calculated as a total of 30 mg of combined active ingredients (sulfadiazine and trimethoprim) per kilogram of the horse’s body weight (kg l.w.) daily. This corresponds to 25 mg of sulfadiazine and 5 mg of trimethoprim per kg l.w. daily.

Frequency is contingent upon the formulation. For the oral paste and powder forms, a schedule of once daily administration is commonly utilized. Conversely, for certain orally administered suspension equivalents, the total daily dose may be divided and administered twice daily.

Administration Protocol and Duration

Correct determination of the horse's body weight is required to determine the dose. The oral paste formulation is deposited on the back of the tongue via a syringe, and the horse's mouth should be free of feed immediately before dosing. After administration, the horse's head is briefly elevated to ensure the paste is swallowed.

The medicine is designed for a short, finite course of treatment. The duration is typically restricted to a maximum of five consecutive days for the oral paste and powder formulations, though longer courses up to 10 days may be utilized for some equivalent formulations.

Research evidence / Overview of Studies for Equibactin

Evidence for use in Respiratory and Systemic Infections

The main body of evidence for Equibactin was studied for Lower Respiratory Tract Infections (LRTIs) in horses caused by certain susceptible bacteria. Research examined these uses through large Randomized Controlled Field Trials (RCTs) involving Adult Horses diagnosed with natural infections. Studies monitored outcomes related to systemic or functional imbalance (like fever and abnormal breathing) and bacteriological clearance. Changes measured in clinical signs were monitored during treatment and observed against the control group. These studies, evaluated in contexts of heightened symptom activity, provide insight into short-term changes in acute respiratory episodes.

Research on Other Labeled Uses

Equibactin was evaluated in settings beyond the respiratory focus, including conditions associated with acute episodes in the gastrointestinal and urogenital systems, as well as wound infections. Evidence is generally supported by General clinical-use data derived from smaller-scale field observations and laboratory data on the spectrum of action. Studies monitored outcomes linked to inflammatory states and tracked episodic changes specific to the infection site. These less-controlled studies provide context but not individual predictions.

Follow-up Duration and Evidence Gaps

The primary RCTs were studied for short-term symptom patterns, with treatment lasting 10 days. Research examined clinical and microbiological status at a defined time point, usually Day 17, to determine the initial post-treatment status. Data for long-term effects remain insufficient beyond this immediate assessment. Follow-up durations were limited, meaning data for the durability of changes over many months remain insufficient. The research highlights what is known over these observation intervals—and what is still uncertain regarding long-term outcomes.

Studies in Specific Populations and Limitations

The main body of evidence was studied for use in a population primarily consisting of Adult Horses. Subgroup findings are uncertain for animals outside of this population, such as younger foals or pregnant mares, where specific research is limited. The evidence quality varies across studies, with the most rigorous study design existing for the primary respiratory indication. Research has examined the maintenance of measured drug concentrations in certain infected tissue compartments. Furthermore, comparative evidence is lacking for many secondary infection uses.

Key Studies & References

1. UNIPRIM® (sulfadiazine and trimethoprim) Powder for Horses, FDA Drug Label and Clinical Summary (NADA 139-257)
2. Evaluation of a randomized, controlled, clinical field trial of trimethoprim/sulfadiazine for lower respiratory tract infections in horses

Common questions about Equibactin (FAQ)

---

Q: How does Equibactin treat a respiratory infection?

According to official regulatory documents, this veterinary medicine is indicated for treating infections in the respiratory tract of horses. It is indicated for use against susceptible bacteria, such as certain Streptococcus and Staphylococcus species, that have shown sensitivity to the combination of sulfadiazine and trimethoprim.

---

Q: What are the common side effects that affect the horse's kidneys?

Official safety information documents specific adverse reactions affecting the urinary and renal systems. These can include haematuria (blood in the urine), crystalluria (crystals forming in the urine), and the obstruction of renal tubules. Regulatory precautions emphasize the importance of ensuring the animal has free access to drinking water to help prevent crystalluria.

---

Q: Are there known long-term side effects after treatment finishes?

Clinical studies have primarily assessed short-term outcomes, with follow-up typically lasting only a defined period after treatment ends. Official information emphasizes that data regarding potential long-term effects, beyond the initial post-treatment assessment period, remain insufficient.

---

Q: What are the necessary safety precautions for the person administering the powder?

The regulatory guidelines stipulate the use of a respirator to avoid dust inhalation and rubber gloves to prevent skin contact when handling the powder formulation. Washing hands thoroughly after administration is a required safety measure to follow.

---

Q: How does Equibactin work as an anti-metabolite?

Equibactin works by utilizing an anti-metabolite strategy, which involves blocking essential metabolic processes in the bacteria. The two active ingredients act via a sequential double blockade in the metabolic pathway responsible for producing essential folate coenzymes, which are critical precursors for the bacteria's DNA, RNA, and protein synthesis.

---

Q: What is the withdrawal period for horses treated with Equibactin before competition?

Official regulatory sources establish a withdrawal period that must be observed for horses intended for the food chain. The official withdrawal period is 14 days for meat and offal. Furthermore, the medicine is not permitted for use in mares whose milk is intended for human consumption.

---

Q: Is Equibactin effective against Streptococcus equi (Strangles)?

The medicine is generally indicated for infections caused by sensitive bacteria, including Streptococcus spp. Official guidance indicates that the decision to use this product for a specific infection, such as Strangles, should be supported by a veterinary assessment and, ideally, the results of susceptibility testing for that particular pathogen.

---

Q: How do I know if my horse has a resistant strain of bacteria?

Official contraindication statements advise against use in cases of known resistance to the sulfadiazine/trimethoprim combination. Identification of a resistant strain is generally determined through laboratory susceptibility testing, as outlined in the regulatory documentation.

---

Q: Can I use this medicine for other animals like dogs or cats?

Official product documentation specifies that this medicine is a veterinary product authorized for use only in the designated target species, which is horses. Using it in other animals is outside the scope of its official authorization.

---

Q: Where can I dispose of unused or expired Equibactin?

Official guidelines mandate that unused or expired veterinary medicinal product and waste materials are not discarded with household waste to prevent environmental contamination. Disposal should be carried out according to local requirements, often through designated national collection schemes.

Official Storage and Disposal Requirements

Storage Conditions and Stability

Equibactin, an oral powder for veterinary use, does not require any special temperature storage conditions. The product must be stored in a dry place and protected from moisture. To ensure stability, containers must be kept tightly closed after first opening. The labeled shelf-life after opening is 3 months for jars and 24 hours for re-closed sachets.

Handling and Safety

Specific handling precautions are mandated when using the powder. To avoid dust inhalation, users should wear a respirator, and to avoid skin contact, rubber gloves are required. Hands must be washed thoroughly after use. The product must be stored where children cannot access it.

Disposal Rules

Any unused product and waste materials derived from the veterinary medicine must be disposed of in accordance with local requirements. Empty containers must be handled according to local authority rules, and the product should not be flushed or discarded into the environment.